The recent U.S. FDA approval of trastuzumab deruxtecan (T-DXd) for HER2-positive solid tumors represents a pivotal advancement, creating new opportunities for targeted therapy in HER2-overexpressing prostate cancer (16–19). This evidence concerns the gene ERBB2 and prostate cancer.